|
Increasing access to antiretroviral drugs would drastically cut AIDS deaths in South Africa
March 27, 2008Increasing US support could save more than a million lives by 2012
More that 1.2 million deaths could be prevented in South Africa over the next five years by accelerating efforts to provide access to antiretroviral therapy (ART), according to a study released online today by the Journal of Infectious Diseases. Using a sophisticated mathematical model of HIV disease and treatment, a team of researchers led by Rochelle Walensky, MD, MPH of Massachusetts General Hospital (MGH) estimated the number of AIDS-related deaths in South Africa through 2012 under alternative ART scale-up assumptions.
The study results underscore the urgent need for Congress to reauthorize the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), which has supported the South African government's effort to increase access to antiretroviral therapy, the researchers note. "If ART is not provided to all who need it, HIV mortality will be enormous," says Walensky. "Deliberate, purposeful, and expedient scale-up will save millions of lives in South Africa alone."
South Africa has one of the largest burdens of HIV infection in the world, with 5 to 6 million individuals and 19 percent of adults aged 15 to 49 infected. While government programs supported by PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria have steadily increased access to antiretrovirals, at the end of 2006 only a third of individuals eligible for the therapy were receiving it.
In order to quantify the potential impact of various strategies for increasing access to ART, the research team projected the number of deaths under five scenarios - ranging from maintaining current access levels, through steady and moderate growth levels, to rapid growth and full access for all patients requiring treatment. Among other factors, calculations were based on the fact that the one-year survival rate for eligible patients who receive antiretroviral therapy is 94 percent, while only 55 percent of those not treated would be expected to survive one year.
Results showed that maintaining current treatment capacity would lead to 2.4 million AIDS-related deaths by 2012. Rapid scale-up, whereby everyone in need would have access by 2011, would reduce the projected number of deaths to 1.2 million during that time period, and immediate full access for all eligible patients would drop deaths to 800,000.
The researchers note that efforts to scale up treatment have resulted in a fivefold increase in access to ART in low and moderate-income countries. "Continued investments in antiretroviral treatment programs worldwide are a public health imperative; the potential loss of life without such support is simply unacceptable," says Walensky, who is an associate professor of Medicine at Harvard Medical School.
Massachusetts General Hospital
South Africa has one of the largest burdens of HIV infection in the world, with 5 to 6 million individuals and 19 percent of adults aged 15 to 49 infected. While government programs supported by PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria have steadily increased access to antiretrovirals, at the end of 2006 only a third of individuals eligible for the therapy were receiving it.
In order to quantify the potential impact of various strategies for increasing access to ART, the research team projected the number of deaths under five scenarios - ranging from maintaining current access levels, through steady and moderate growth levels, to rapid growth and full access for all patients requiring treatment. Among other factors, calculations were based on the fact that the one-year survival rate for eligible patients who receive antiretroviral therapy is 94 percent, while only 55 percent of those not treated would be expected to survive one year.
Results showed that maintaining current treatment capacity would lead to 2.4 million AIDS-related deaths by 2012. Rapid scale-up, whereby everyone in need would have access by 2011, would reduce the projected number of deaths to 1.2 million during that time period, and immediate full access for all eligible patients would drop deaths to 800,000.
The researchers note that efforts to scale up treatment have resulted in a fivefold increase in access to ART in low and moderate-income countries. "Continued investments in antiretroviral treatment programs worldwide are a public health imperative; the potential loss of life without such support is simply unacceptable," says Walensky, who is an associate professor of Medicine at Harvard Medical School.
Massachusetts General Hospital
Antiretroviral Therapy News and Current Antiretroviral Therapy Events RSSTuberculosis presents major challenges to HIV treatment in developing countries
Human immunodeficiency virus (HIV) care and treatment programs in resource-limited settings must aggressively address tuberculosis (TB) and the emerging multidrug-resistant TB epidemic to save patient lives and to curb the global TB burden, a major cause of death for persons with HIV.
Asthma risk increases in children treated for HIV
Children whose immune systems rebound after treatment with potent anti-viral drugs for HIV infection face an increased risk of developing asthma, said a federally funded consortium of researchers led by those from Baylor College of Medicine in a report that appears online in the Journal of Allergy and Clinical Immunology.
Challenges of HIV-1 subtype diversity
A review article in the New England Journal of Medicine explores the genetic variation of HIV-1 and its implications for preventing and treating the disease. Francine McCutchan, Ph.D., a researcher with the U.S. Military HIV Research Program, co-authored the article, which appeared in the April 10, 2008 edition.
Climate change threats to HIV rates
Social factors, including economic pressures caused by climate change, could lead to an increase in HIV infection rates world-wide, warns a leading researcher from the University of New South Wales (UNSW).
Study shows common vitamin and other micronutrient supplements reduce risks of TB recurrence
New findings show a link between micronutrient supplementation and reduced risk of recurrence during tuberculosis chemotherapy, according to a study published in the June 1 issue of The Journal of Infectious Diseases, now available online.
When should children infected with HIV start medication
The advent of effective medications for treating HIV dramatically improved the outlook for both adults and children infected with HIV who had access to treatment, but the optimal timing for starting treatment remains controversial, particularly in children.
HIV persists in the gut despite long-term HIV therapy
Even with effective anti-HIV therapies, doctors still have not been able to eradicate the virus from infected individuals who are receiving such treatments, largely because of the persistence of HIV in hideouts known as viral reservoirs.
New York City death rate reaches historic low
The death rate in New York City reached an all-time low in 2006, the Health Department reported today, as the number of deaths fell to 55,391 -- down from 57,068 in 2005 and 60,218 in 2001.
Doctors failing to diagnose HIV early in UK Africans
Doctors are missing valuable opportunities to diagnose HIV in Africans living in the UK, with serious consequences for their long term health, according to research funded by the Wellcome Trust.
Women with AIDS face cervical cancer threat
According to a report issued last week by UNAIDS, access to antiretroviral therapy is beginning to reduce AIDS mortality worldwide.
More Antiretroviral Therapy News Articles
| © 2008 BrightSurf.com |